VIATRIS INC. Research and Development Expense
VIATRIS INC. (VTRS) reported Research and Development Expense of $248.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- VIATRIS INC. research and development expense for the quarter ending 2026-06-30 was $248.30M, a 13.48% increase year-over-year.
- VIATRIS INC. research and development expense for the quarter ending 2026-03-31 was $248.60M, a 11.98% increase year-over-year.
- VIATRIS INC. research and development expense for the quarter ending 2025-09-30 was $250.40M, a 26.21% increase year-over-year.
- VIATRIS INC. research and development expense for the quarter ending 2025-06-30 was $218.80M, a 7.20% increase year-over-year.
- VIATRIS INC. research and development expense for fiscal 2021 was $751.10M, a 35.31% increase from fiscal 2020.
- VIATRIS INC. research and development expense for fiscal 2020 was $555.10M, a 13.25% decline from fiscal 2019.
- VIATRIS INC. research and development expense for fiscal 2019 was $639.90M, a 9.17% decline from fiscal 2018.
- VIATRIS INC. research and development expense for fiscal 2018 was $704.50M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $248.30M 10-Q · filed 2026-08-06 | $496.90M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $248.60M 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | $250.40M 10-Q · filed 2025-11-06 | $469.20M derived: sum of 2 quarters · filed 2026-08-06 | $691.20M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $218.80M 10-Q · filed 2026-08-06 | $440.80M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $222.00M 10-Q · filed 2026-05-07 | |||
| 2024-09-30 | $198.40M 10-Q · filed 2025-11-06 | $402.50M derived: sum of 2 quarters · filed 2025-11-06 | $602.20M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $204.10M 10-Q · filed 2025-08-07 | $403.80M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $199.70M 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | $211.20M 10-Q · filed 2024-11-07 | $419.50M derived: sum of 2 quarters · filed 2024-11-07 | $602.40M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $208.30M 10-Q · filed 2024-08-08 | $391.20M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $182.90M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $174.90M 10-Q · filed 2023-11-08 | $337.50M derived: sum of 2 quarters · filed 2023-11-08 | $479.80M 10-Q · filed 2023-11-08 | $747.00M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $162.60M 10-Q · filed 2023-08-07 | $304.90M 10-Q · filed 2023-08-07 | $572.10M derived: sum of 3 quarters · filed 2023-08-07 | $724.20M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $142.30M 10-Q · filed 2023-05-08 | $409.50M derived: sum of 2 quarters · filed 2023-05-08 | $561.60M derived: sum of 3 quarters · filed 2023-05-08 | $709.30M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $267.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $419.30M derived: sum of 2 quarters · filed 2022-11-07 | $567.00M derived: sum of 3 quarters · filed 2022-11-07 | $751.10M 10-K · filed 2022-02-28 |
| 2021-09-30 | $152.10M 10-Q · filed 2022-11-07 | $299.80M derived: sum of 2 quarters · filed 2022-11-07 | $483.90M 10-Q · filed 2022-11-07 | $638.70M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $147.70M 10-Q · filed 2022-08-08 | $331.80M 10-Q · filed 2022-08-08 | $486.60M derived: sum of 3 quarters · filed 2022-08-08 | $616.40M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $184.10M 10-Q · filed 2022-05-09 | $338.90M derived: sum of 2 quarters · filed 2022-05-09 | $468.70M derived: sum of 3 quarters · filed 2022-05-09 | $625.00M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $154.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $284.60M derived: sum of 2 quarters · filed 2022-02-28 | $440.90M derived: sum of 3 quarters · filed 2022-02-28 | $555.10M 10-K · filed 2022-02-28 |
| 2020-09-30 | $129.80M 10-Q · filed 2021-11-08 | $286.10M derived: sum of 2 quarters · filed 2021-11-08 | $400.30M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $156.30M 10-Q · filed 2021-08-09 | $270.50M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $114.20M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $639.90M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $704.50M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |